Clinical trial
Efficacy, Safety, and Tolerability of Oral Cebranopadol Versus Morphine Sulfate PR in Subjects With Chronic Moderate to Severe Pain Related to Cancer.
NCT01964378 is registered in ClinicalTrials.gov with Tris Pharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy, Safety, and Tolerability of Oral Cebranopadol Versus Morphine Sulfate PR in Subjects With Chronic Moderate to Severe Pain Related to Cancer.
- Lead sponsor
- Tris Pharma, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- October 29, 2013
- Completion date
- October 16, 2015
- Enrollment
- 200 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.